Get to know our clinical trials
Ensayo clínico de Seguridad, farmacocinética (FC) y eficacia preliminar de AMX-500 en el cáncer de próstata metastásico resistente a la castración (CPRCm). castración (CPRCm).
THE MAIN OBJECTIVE IS TO EVALUATE THE SAFETY AND TOLERABILITY OF INCREASING DOSES OF AMX-500 AS MONOTHERAPY (PART 1) AND IN COMBINATION WITH ANOTHER THERAPEUTIC AGENT (PART 3).
Technical Summary
- FIRST-IN-HUMAN PHASE I STUDY OF THE SAFETY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF AMX-500 IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC).
- Code EudraCT: 2023-503495-24
- Protocol number: AMX-500-001
- Promoter: Amunix Pharmaceuticals, Inc.
- Molecule/Drug: AMX-500
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Who can participate?
Safety, pharmacokinetics (PK) and preliminary efficacy clinical trial of AMX-500 in metastatic castration-resistant prostate cancer (mCRPC). castration (mCRPC).
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.